Epidermolysis bullosa, lethal acantholytic

From WikiMD's WELLNESSPEDIA

Alternate names[edit]

EBLA

Definition[edit]

Lethal acantholytic epidermolysis bullosa is a suprabasal subtype of epidermolysis bullosa simplex (EBS) characterized by generalized oozing erosions, usually in the absence of blisters.

Epidemiology[edit]

Prevalence is unknown but 3 cases have been reported to date.

Cause[edit]

  • This form of EBS is due to mutations in the DSP (6p24) gene encoding desmoplakin.
  • A homozygous nonsense mutation in the JUP gene (17q21) has been reported in a patient with a very similar phenotype.

Inheritance[edit]

Autosomal recessive inheritance, a 25% chance

Transmission is autosomal recessive.

Onset[edit]

Onset of the disease is at birth.

Signs and symptoms[edit]

  • Erosions are associated with absent nails, universal alopecia, and, in one patient, neonatal teeth.
  • Extracutaneous involvement is always present, involving erosions of the soft tissues of the oral cavity, and gastrointestinal, genitourinary and respiratory tract abnormalities.
  • Cardiomyopathy has been reported in one case.

For most diseases, symptoms will vary from person to person. People with the same disease may not have all the symptoms listed. 80%-99% of people have these symptoms

  • Alopecia(Hair loss)
  • Anonychia(Absent nails)
  • Oral mucosal blisters(Blisters of mouth)
  • Skin erosion

5%-29% of people have these symptoms

  • Cardiomegaly(Enlarged heart)
  • Cardiomyopathy(Disease of the heart muscle)
  • Esophageal ulceration(Esophagus ulcer)
  • Natal tooth(Born with teeth)

Diagnosis[edit]

Treatment[edit]

Prognosis[edit]

In reported cases, death occurred within the first month of life from multiorgan failure secondary to huge transcutaneous fluid loss or airway obstruction due to mucosal sloughing.





Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.